Status:
COMPLETED
Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease
Lead Sponsor:
IntelGenx Corp.
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
The aim of this study is to evaluate the safety, feasibility, tolerability and efficacy of a new buccal film of montelukast in patients with mild to moderate Alzheimer's disease.
Detailed Description
This is a randomized Phase IIa, multi-center, double-blind, placebo-controlled study of a new buccal film of montelukast in patients with mild to moderate Alzheimer's Disease. Study drug (montelukast ...
Eligibility Criteria
Inclusion
- Mild to moderate Alzheimer's Disease.
- MMSE score of 14 - 22
- CT or MRI within 18 months prior to screening indicating clinical phenotype of Alzheimer's Disease
- Treated daily with donepezil, rivastigmine or galantamine for ≥ 3 months
- All other medications for chronic conditions should have been at a stable dose for at least 2 weeks prior to first dose.
- No clinically meaningful abnormalities on electrocardiogram (ECG), physical examination and clinical laboratory tests
Exclusion
- Taken memantine within 2 months prior to screening.
- Current diagnosis of any psychiatric disorder, depression that is not well-controlled, clinically significant or unstable systemic disease, or severe medical procedures
- Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation.
- Patients at imminent risk of self-harm, based on clinical interview and response on S-STS
- History of malignancy occurring within 5 years immediately prior to screening, except for a subject who has been adequately treated for (1) basal cell or squamous cell skin cancer, (2) in situ cervical cancer, (3) localized prostate carcinoma, or (4) who has undergone potentially curative therapy with no evidence of recurrence for more than 3 years post-therapy, and who is deemed at low risk for recurrence by her/his treating physician
- History of any of the following cardiovascular conditions that an unstable:
- Hypotension
- Hypertension
- Active cardiovascular disease
- Evidence of cerebrovascular disease
- Have used or plan to use the following medications from 30 days prior to Visit 1 through the end of the study:
- Narcotic analgesics more frequently than on three days per week as needed for pain;
- Daily antipsychotic (except for risperidone, quetiapine and aripiprazole, and only if at a stable and controlled dose)
- Daily anxiolytic use; however, occasional use as needed for acute agitation or to be used as a rescue anxiolytic (i.e., lorazepam and oxazepam) is acceptable as long as not used within 24 hours of a clinic visit window;
- Daily antidepressants (except for citalopram, escitalopram, venlafaxine, trazodone, sertraline, and mirtazapine, and only if at a stable and controlled dose);
- Low potency antipsychotic agents (eg chlorpromazine) - not permitted at any time during the study;
- Anti-parkinson's disease medications (selegiline, levodopa, amantadine) for the treatment of Parkinson's Syndrome Complex;
- Lithium;
- Clozapine;
- Previously treated with or currently using montelukast
Key Trial Info
Start Date :
November 26 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 3 2024
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT03402503
Start Date
November 26 2018
End Date
April 3 2024
Last Update
April 18 2024
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Vancouver Island Health Authority
Victoria, British Columbia, Canada, V8R 1J8
2
Centricity Research (formerly True North Clinical Research)
Halifax, Nova Scotia, Canada, B3S 1N2
3
Centricity Research (formerly True North Clinical Research)
New Minas, Nova Scotia, Canada, B4N 3R7
4
Bruyère Research Institute
Ottawa, Ontario, Canada, K1N 5C8